Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Correspondence

Lenalidomide plus Rituximab for Mantle-Cell Lymphoma

To the Editor: Ruan et al. (Nov. 5 issue)1 report that combination therapy consisting of lenalidomide plus rituximab was highly effective in patients with previously untreated mantle-cell lymphoma. However, several large clinical studies have shown promising results with high-dose chemotherapy followed by autologous stem-cell transplantation as initial consolidation therapy.2,3 Also, the recent European Society for Blood and Marrow Transplantation–European Mantle Cell Lymphoma Network consensus project recommended autologous stem-cell transplantation even for patients who were deemed to have low-risk disease according to their score on the Mantle Cell Lymphoma International Prognostic Index.4Our concern regarding the lenalidomide-based regimen is that . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Print Subscriber? Activate your online access.